← Human Trials & Peer-Reviewed Studies

Effects of vitamin D on cardiovascular disease risk factors in polycystic ovary syndrome women with vitamin D deficiency.

Plain-language guide to PMID 22453059 (2013): double-blind randomized controlled trial of Vitamin D, K2, Magnesium and Zinc.

Key Facts

PMID
22453059
Journal
Journal of endocrinological investigation
Year
2013
Study type
Randomized Controlled Trial
Authors
Rahimi-Ardabili H et al. (3 authors)
DOI
10.3275/8303

What This Study Did, in Plain Language

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc.

To investigate the effect of cholecalciferol on CVD risk factors in PCOS women with vitamin D deficiency.

Why It Was Studied

Vitamin D deficiency is prevalent among women, including patients with polycystic ovary syndrome (PCOS).

There is very limited data on the vitamin D effect on CVD risk factors in women with PCOS and vitamin D deficiency.

Who Took Part

The age groups tagged for this paper are young adults and adults, both men and women.

Serum vitamin D, PTH, lipid profile, apolipoprotein AI (APO-AI), and high sensitive C- reactive protein (hs-CRP) were measured at baseline and after treatment.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

Neither the participants nor the staff measuring them knew who was on Vitamin D, K2, Magnesium and Zinc, so expectations could not easily colour the readings.

A placebo (an inactive look-alike) gave the Vitamin D, K2, Magnesium and Zinc group a baseline to be compared against.

The study was a randomized, placebo-controlled, double blinded trial.

What Was Measured

Topics PubMed links to this paper include C-Reactive Protein, Cardiovascular Diseases, Cholesterol, HDL, Cholesterol, LDL, Lipids, Polycystic Ovary Syndrome and Prognosis.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc.

Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2013 (Journal of endocrinological investigation), a journal based in Italy.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.

Our Notes on the Compound

Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.

Related Pages

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.